SCHEMBL2897775

SCHEMBL2897775

CCOC(=O)N1CCN([C@H](C)c2nnn(-c3cc(Cl)ccc3F)n2)CC1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
IDE P14735 1/20 0.43
KCNH2 Q12809 1/20 0.43
MAPT P10636 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
TSHR P16473 1/20 0.41
CHRM2 P08172 1/20 0.40
CHRM1 P11229 1/20 0.40
HTT P42858 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ATM Q13315 1/20 0.40
NOS1 P29475 1/20 0.40
NOS2 P35228 1/20 0.40
POLB P06746 1/20 0.40
ALDH1A1 P00352 2/20 0.39
ALOX15 P16050 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2892876 1.00 KMT2A (0.45) KMT2AMEN1IDEKCNH2MAPT
SCHEMBL2892874 1.00 KMT2A (0.45) KMT2AMEN1IDEKCNH2MAPT
SCHEMBL27648781 0.87 CYP3A4 (0.36) KMT2AMEN1ALDH1A1
SCHEMBL2889476 0.84 GRM5 (0.45) KMT2AMEN1KCNH2MAPTSMN1; SMN2
SCHEMBL2889444 0.84 GRM5 (0.45) KMT2AMEN1KCNH2MAPTSMN1; SMN2
SCHEMBL2889474 0.84 GRM5 (0.45) KMT2AMEN1KCNH2MAPTSMN1; SMN2
SCHEMBL2889528 0.80 KCNH2 (0.58) KMT2AMEN1IDEKCNH2MAPT
SCHEMBL5739047 0.79 KCNH2 (0.49) KMT2AMEN1IDEKCNH2MAPT
SCHEMBL5958602 0.74 KCNH2 (0.68) KMT2AMEN1IDEKCNH2MAPT
SCHEMBL5958623 0.74 KCNH2 (0.68) KMT2AMEN1IDEKCNH2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691892-B2 Tetrazole compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2010-04-06 US claimed
US-20070197549-A1 Tetrazole compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2007-08-23 US claimed
EP-1716125-A1 TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS AstraZeneca AB (SE) 2006-11-02 EP claimed
US-20060004021-A1 Tetrazole compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB 2006-01-05 US claimed
WO-2005080356-A1 TETRAZOLE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONITS ASTRAZENECA AB (SE) 2005-09-01 WO claimed
US-7691892-B2 Tetrazole compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2010-04-06 US disclosed
US-20070197549-A1 Tetrazole compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB (SE) 2007-08-23 US disclosed
US-20060004021-A1 Tetrazole compounds and their use as metabotropic glutamate receptor antagonists ASTRAZENECA AB 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004021-A1 Tetrazole compounds and their use as metabotropic glutamate receptor antagonists GRM1, GRM3, GRM4 KMT2A 2233/4885MEN1 2336/4885IDE 4842/4885
US-20070197549-A1 Tetrazole compounds and their use as metabotropic glutamate receptor antagonists GRM1, GRM3, GRM4 KMT2A 2227/4885MEN1 2406/4885IDE 4845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.